Annexon Inc
ANNX2.554USD
+0.104+4.25%
Market hours （ET）Quotes delayed by 15 min
280.23MMarket Cap
LossP/E TTM
More Details of Annexon Inc Company
Annexon, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing a late-stage clinical platform of therapies for people living with classical complement-mediated neuroinflammatory diseases of the body, brain, and eye. Using its platform, it is identifying and characterizing the role of the complement pathway in three therapeutic areas: autoimmune, neurodegeneration and ophthalmology. Its lead candidate, ANX005, is an investigational monoclonal antibody (mAb), formulated for intravenous administration in a pivotal Phase III clinical trial for the treatment of patients with Guillain-Barre Syndrome (GBS). It is evaluating ANX007, an antigen-binding fragment (Fab), formulated for intravitreal administration, for the potential treatment of patients with geographic atrophy (GA). It is developing ANX1502, which is an oral small molecule for the treatment of autoimmune indications. It has developed ANX009, a C1q-blocking Fab formulated for subcutaneous delivery.
Company Info
Ticker SymbolANNX
Company nameAnnexon Inc
IPO dateJul 24, 2020
CEOMr. Douglas E. Love, Esq.
Number of employees100
Security typeOrdinary Share
Fiscal year-endJul 24
Address1400 Sierra Point Parkway
CityBRISBANE
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code94005
Phone16508225500
Websitehttps://annexonbio.com/
Ticker SymbolANNX
IPO dateJul 24, 2020
CEOMr. Douglas E. Love, Esq.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Michael Overdorf
Mr. Michael Overdorf
Executive Vice President, Chief Business Officer
Executive Vice President, Chief Business Officer
81.75K
-1.03%
Ms. Jennifer Lew
Ms. Jennifer Lew
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
81.33K
-1.35%
Dr. Ted Yednock, Ph.D.
Dr. Ted Yednock, Ph.D.
Executive Vice President, Chief Innovation Officer
Executive Vice President, Chief Innovation Officer
24.66K
-4.33%
Dr. Jamie Dananberg, M.D.
Dr. Jamie Dananberg, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
7.48K
-90.47%
Dr. Dean Rick Artis, Ph.D.
Dr. Dean Rick Artis, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
--
--
Mr. William D. Waddill
Mr. William D. Waddill
Independent Director
Independent Director
--
--
Ms. Jung E. Choi
Ms. Jung E. Choi
Independent Director
Independent Director
--
--
Dr. William H. Carson, M.D.
Dr. William H. Carson, M.D.
Independent Director
Independent Director
--
--
Mr. Muneer A. Satter, J.D.
Mr. Muneer A. Satter, J.D.
Independent Director
Independent Director
--
--
Mr. William (Bj) Jones, Jr.
Mr. William (Bj) Jones, Jr.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Michael Overdorf
Mr. Michael Overdorf
Executive Vice President, Chief Business Officer
Executive Vice President, Chief Business Officer
81.75K
-1.03%
Ms. Jennifer Lew
Ms. Jennifer Lew
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
81.33K
-1.35%
Dr. Ted Yednock, Ph.D.
Dr. Ted Yednock, Ph.D.
Executive Vice President, Chief Innovation Officer
Executive Vice President, Chief Innovation Officer
24.66K
-4.33%
Dr. Jamie Dananberg, M.D.
Dr. Jamie Dananberg, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
7.48K
-90.47%
Dr. Dean Rick Artis, Ph.D.
Dr. Dean Rick Artis, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
--
--
Mr. William D. Waddill
Mr. William D. Waddill
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, May 17
Updated: Sat, May 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
12.09%
BlackRock Institutional Trust Company, N.A.
6.94%
Alerce Investment Management, L.P.
6.75%
BVF Partners L.P.
6.38%
Logos Global Management LP
6.02%
Other
61.82%
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
12.09%
BlackRock Institutional Trust Company, N.A.
6.94%
Alerce Investment Management, L.P.
6.75%
BVF Partners L.P.
6.38%
Logos Global Management LP
6.02%
Other
61.82%
Shareholder Types
Shareholders
Proportion
Investment Advisor
46.58%
Investment Advisor/Hedge Fund
22.00%
Hedge Fund
18.07%
Private Equity
6.75%
Venture Capital
6.07%
Research Firm
2.33%
Bank and Trust
0.73%
Individual Investor
0.57%
Endowment Fund
0.44%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
324
113.85M
103.77%
-22.18M
2025Q1
339
111.61M
101.75%
-29.54M
2024Q4
329
116.73M
106.58%
-17.05M
2024Q3
303
113.54M
107.51%
-18.37M
2024Q2
291
110.25M
106.60%
-6.79M
2024Q1
286
95.95M
106.04%
-7.64M
2023Q4
274
81.06M
103.56%
+7.91M
2023Q3
277
55.43M
104.79%
-23.79M
2023Q2
273
56.90M
107.89%
-13.92M
2023Q1
276
56.74M
113.00%
-7.66M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Fidelity Management & Research Company LLC
13.26M
12.09%
-961.15K
-6.76%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
7.62M
6.94%
+55.22K
+0.73%
Mar 31, 2025
Alerce Investment Management, L.P.
7.41M
6.75%
--
--
Mar 31, 2025
BVF Partners L.P.
7.00M
6.38%
--
--
Mar 31, 2025
Logos Global Management LP
6.60M
6.02%
+2.60M
+65.00%
Apr 21, 2025
Redmile Group, LLC
6.30M
5.74%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
5.36M
4.89%
-167.26K
-3.02%
Mar 31, 2025
Bain Capital Life Sciences Investors, LLC
5.25M
4.78%
--
--
Mar 31, 2025
Bellevue Asset Management AG
5.16M
4.7%
--
--
Mar 31, 2025
Sio Capital Management, LLC
3.40M
3.1%
+1.03M
+43.55%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
Virtus LifeSci Biotech Clinical Trials ETF
0.8%
iShares Neuroscience and Healthcare ETF
0.56%
ALPS Medical Breakthroughs ETF
0.18%
iShares Micro-Cap ETF
0.05%
ProShares Ultra Nasdaq Biotechnology
0.03%
Invesco Nasdaq Biotechnology ETF
0.03%
Avantis US Small Cap Equity ETF
0.03%
iShares Russell 2000 Value ETF
0.02%
iShares Biotechnology ETF
0.02%
ProShares Hedge Replication ETF
0.01%
View more
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.8%
iShares Neuroscience and Healthcare ETF
Proportion0.56%
ALPS Medical Breakthroughs ETF
Proportion0.18%
iShares Micro-Cap ETF
Proportion0.05%
ProShares Ultra Nasdaq Biotechnology
Proportion0.03%
Invesco Nasdaq Biotechnology ETF
Proportion0.03%
Avantis US Small Cap Equity ETF
Proportion0.03%
iShares Russell 2000 Value ETF
Proportion0.02%
iShares Biotechnology ETF
Proportion0.02%
ProShares Hedge Replication ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
